TISIDB

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00651 BTB/POZ domain
Function	Function as a transcriptional repressor for PRDM1.

> Gene Ontology [ TOP ]
Biological Process	GO:0002521 leukocyte differentiation GO:0002573 myeloid leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002761 regulation of myeloid leukocyte differentiation GO:0002762 negative regulation of myeloid leukocyte differentiation GO:0030099 myeloid cell differentiation GO:0030224 monocyte differentiation GO:0030225 macrophage differentiation GO:0030851 granulocyte differentiation GO:0030852 regulation of granulocyte differentiation GO:0030853 negative regulation of granulocyte differentiation GO:0045637 regulation of myeloid cell differentiation GO:0045638 negative regulation of myeloid cell differentiation GO:0045649 regulation of macrophage differentiation GO:0045650 negative regulation of macrophage differentiation GO:0045655 regulation of monocyte differentiation GO:0045656 negative regulation of monocyte differentiation GO:0097028 dendritic cell differentiation GO:1902105 regulation of leukocyte differentiation GO:1902106 negative regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903131 mononuclear cell differentiation GO:1903706 regulation of hemopoiesis GO:1903707 negative regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:2001198 regulation of dendritic cell differentiation GO:2001199 negative regulation of dendritic cell differentiation GO:2001200 positive regulation of dendritic cell differentiation
Molecular Function	-
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ZBTB46 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ZBTB46 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
25446897	Melanoma	Promote immunity	Within these, CD103(+) DCs are extremely sparse and yet remarkably capable CTL stimulators. These are uniquely dependent on IRF8, Zbtb46, and Batf3 transcription factors and are generated by GM-CSF and FLT3L cytokines. Regressing tumors have higher proportions of these cells, T-cell-dependent immune clearance relies on them, and abundance of their transcripts in human tumors correlates with clinical outcome.

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ZBTB46 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ZBTB46 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.281	0.331
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.353	0.641
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.233	0.721
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.064	0.874
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.586	0.746
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.598	0.8
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.434	0.228
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.466	0.577
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.428	0.63
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.432	0.608
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.196	0.27
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.228	0.0759

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ZBTB46 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	0	23.1	0.223
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZBTB46. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZBTB46. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZBTB46. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZBTB46. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ZBTB46 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ZBTB46 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Aliases	FLJ13502; BZEL; BTB-ZF protein expressed in effector lymphocytes; ZNF340; BTBD4; BTB (POZ) domain containing ......
Chromosomal Location	20q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ZBTB46 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ZBTB46